Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of PTC518 in Huntington's disease has completed. Results have been posted (2026-01-13) by PTC Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• PTC518

Snippet

Sponsor: PTC Therapeutics | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-01-13